Literature DB >> 20663222

Lipoprotein (a), C-reactive protein and some metabolic cardiovascular risk factors in type 2 DM.

Anthonia O Ogbera1, Alfred O Azenabor.   

Abstract

BACKGROUND: Lipoprotein (a) (LP (a) is an independent cardiovascular risk factor that is not widely studied in people of sub-Saharan African origin. The aim of this report is to determine the frequency of occurrence of elevated Lp (a) and possible relationship with total cholesterol (TCHOL), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglycerides (TG), C reactive protein (CRP) and serum uric acid (SUA).
METHODS: This is a cross sectional study carried out in 200 Nigerian patients with type 2 DM and 100 sex and age matched healthy Controls aged between 32-86 years. We determined the frequency of occurrence of elevated Lp (a) levels in the study subjects and compared clinical and biochemical variables between type 2 diabetic patients and non-diabetic patients. Clinical and biochemical parameters were also compared between subjects with type 2 DM who had elevated LP (a) and normal LP (a) levels. Long term glycaemic control using glycosylated haemoglobin was determined and compared in the study subjects. Test statistics used include chi square, correlation coefficient analysis and Student's t test.
RESULTS: The mean Lp(a) concentration differed significantly between type 2 diabetic patients and the Control subjects (18.7 (5.8) mg/dl vs 23 (6.8) mg/dl, 0.00001). Similarly, the prevalence of high LP (a) levels in type 2 DM patients was significantly higher than that of the Control subjects (12.5% vs 4%, p-0.019). The mean levels of the lipid profile parameters (TCHOL, LDL-C, TG, LDL/HDL) and CRP were significantly higher in DM patients than in the Control subjects. The mean LP (a) levels were comparable in both sexes and in DM subjects with and without hypertension. TG was the only parameter that differed significantly between subjects with elevated Lp (a) levels and those with normal Lp (a) levels. There was a significant positive correlation (r) between Lp(a) levels and TG, LDL-C. TCHOL, LDL/HDL and uric acid. No association was found between Lp(a) and clinical parameters such as age and anthropometric indices.
CONCLUSION: We have showed that Lp (a), CRP and other CVS risk factors cluster more in patients with DM than non DM patients. Serum Lp (a) levels are not associated with anthropometric and glycaemic indices.

Entities:  

Year:  2010        PMID: 20663222      PMCID: PMC2919447          DOI: 10.1186/1758-5996-2-51

Source DB:  PubMed          Journal:  Diabetol Metab Syndr        ISSN: 1758-5996            Impact factor:   3.320


  22 in total

1.  A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity.

Authors:  L L ABEL; B B LEVY; B B BRODIE; F E KENDALL
Journal:  J Biol Chem       Date:  1952-03       Impact factor: 5.157

Review 2.  Physiological and clinical importance of lipoprotein(a).

Authors:  L Romics; I Karádi; A Császár; G M Kostner
Journal:  Tokai J Exp Clin Med       Date:  1990-05

3.  Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study.

Authors:  E Bonora; G Targher; M B Zenere; F Saggiani; V Cacciatori; F Tosi; D Travia; M G Zenti; P Branzi; L Santi; M Muggeo
Journal:  Int J Obes Relat Metab Disord       Date:  1996-11

4.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

5.  Quantitative determination of serum triglycerides by the use of enzymes.

Authors:  G Bucolo; H David
Journal:  Clin Chem       Date:  1973-05       Impact factor: 8.327

6.  C-reactive protein and glycemic control in adults with diabetes.

Authors:  Dana E King; Arch G Mainous; Thomas A Buchanan; William S Pearson
Journal:  Diabetes Care       Date:  2003-05       Impact factor: 19.112

7.  Serum lipoprotein(a) in patients with diabetes mellitus.

Authors:  F R Heller; J Jamart; P Honore; G Derue; V Novik; L Galanti; A Parfonry; J C Hondekijn; M Buysschaert
Journal:  Diabetes Care       Date:  1993-05       Impact factor: 19.112

8.  High risk levels of lipoprotein(a) in Pakistani patients with type 2 diabetes mellitus.

Authors:  Syed S Habib; Muhammad Aslam
Journal:  Saudi Med J       Date:  2003-06       Impact factor: 1.484

9.  Plasma lipids, lipoproteins, and apolipoproteins in Nigerian diabetes mellitus, essential hypertension, and hypertensive-diabetic patients.

Authors:  O O Oyelola; A A Ajayi; R O Babalola; E A Stein
Journal:  J Natl Med Assoc       Date:  1995-02       Impact factor: 1.798

10.  Uric acid and the development of metabolic syndrome in women and men.

Authors:  Xuemei Sui; Timothy S Church; Rebecca A Meriwether; Felipe Lobelo; Steven N Blair
Journal:  Metabolism       Date:  2008-06       Impact factor: 8.694

View more
  6 in total

1.  Lipoprotein (a) and atherogenic indices in Sudanese patients with type 2 diabetes.

Authors:  Abdelmarouf H Mohieldein; Khairia Eltahir Abdalla; Marghoob Hasan
Journal:  Int J Health Sci (Qassim)       Date:  2014-07

2.  Acute phase reactant dynamics and incidence of microvascular dysfunctions in type 2 diabetes mellitus.

Authors:  Alfred Azenabor; Anthonia O Ogbera; Ngozi E Adejumo; Adejimi O Adejare
Journal:  J Res Med Sci       Date:  2011-10       Impact factor: 1.852

3.  Does atorvastatin work more effectively than biguanides in reducing cardiovascular risk factors?

Authors:  Afshan Siddiq; Rafeeq Alam Khan; Sadia Ghousia Baig
Journal:  J Pharm Bioallied Sci       Date:  2011-04

4.  Serum Lipoprotein (a) Levels in Black South African Type 2 Diabetes Mellitus Patients.

Authors:  Jim Joseph; Farzana Ganjifrockwala; Grace George
Journal:  Oxid Med Cell Longev       Date:  2016-10-19       Impact factor: 6.543

5.  Variations of lipoprotein(a) levels in the metabolic syndrome: a report from the Maracaibo City Metabolic Syndrome Prevalence Study.

Authors:  Valmore Bermúdez; Joselyn Rojas; Juan Salazar; Luis Bello; Roberto Añez; Alexandra Toledo; Maricarmen Chacín; Miguel Aguirre; Marjorie Villalobos; Mervin Chávez; María Sofía Martínez; Wheeler Torres; Yaquelin Torres; José Mejías; Edgardo Mengual; Liliana Rojas; Milagro Sánchez de Rosales; Ana Quevedo; Raquel Cano; Mayela Cabrera; Rafael París; Adonías Lubo; María Montiel; Climaco Cano
Journal:  J Diabetes Res       Date:  2013-04-22       Impact factor: 4.011

6.  Investigating the Atherogenic Risk of Lipoprotein(a) in Type 2 Diabetic Patients.

Authors:  Jagannadha R Peela; Omar B Latiwesh; Farag Elshaari; Azhar Hussain; Elsa Tabrez; Emily Viglianco; Ajené Edwards; Farwa Ali; Avinash K Rawal
Journal:  Cureus       Date:  2018-07-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.